GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » PS Ratio

Radiopharm Theranostics (ASX:RAD) PS Ratio : (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Radiopharm Theranostics's share price is A$0.033. Radiopharm Theranostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Hence, Radiopharm Theranostics's PS Ratio for today is .

The historical rank and industry rank for Radiopharm Theranostics's PS Ratio or its related term are showing as below:

ASX:RAD' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 135
Current: 33.94

During the past 2 years, Radiopharm Theranostics's highest PS Ratio was 135.00. The lowest was 0.00. And the median was 0.00.

ASX:RAD's PS Ratio is ranked worse than
73.97% of 999 companies
in the Biotechnology industry
Industry Median: 9.3 vs ASX:RAD: 33.94

Radiopharm Theranostics's Revenue per Sharefor the six months ended in Dec. 2023 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Radiopharm Theranostics was -100.00% per year.

Back to Basics: PS Ratio


Radiopharm Theranostics PS Ratio Historical Data

The historical data trend for Radiopharm Theranostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics PS Ratio Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
PS Ratio
- 110.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio - - - - -

Competitive Comparison of Radiopharm Theranostics's PS Ratio

For the Biotechnology subindustry, Radiopharm Theranostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's PS Ratio falls into.



Radiopharm Theranostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Radiopharm Theranostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.033/0
=

Radiopharm Theranostics's Share Price of today is A$0.033.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Radiopharm Theranostics  (ASX:RAD) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Radiopharm Theranostics PS Ratio Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (ASX:RAD) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines